![Roland Kolbeck](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 124 748 $ al 31/07/2026
Dr. Roland Kolbeck is a Chief Scientific Officer at Aclaris Therapeutics, Inc. Dr. Kolbeck was previously employed as a Chief Scientific Officer by Spirovant Sciences, Inc. He received his graduate degree from the University of Regensburg.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/08/2026 | 23.990 ( 0,02 % ) | 124 748 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ACLARIS THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 28/07/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
Spirovant Sciences, Inc.
 Spirovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Engages in development, manufacturing of pharmaceuticals related to gene therapy | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Aclaris Therapeutics, Inc.
 Aclaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel drug candidates for immuno-inflammatory diseases | Health Technology |
University of Regensburg
 University of Regensburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Spirovant Sciences, Inc.
Spirovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Engages in development, manufacturing of pharmaceuticals related to gene therapy | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
